Cytokines and Cytokine Receptors

October 14-18, 1995
The Sagamore, Bolton Landing (Lake George), New York

CONFEREE CHAIRPERSONS

Steven Gillis / Seattle, WA
Douglas E. Williams / Seattle, WA

SCIENTIFIC PROGRAM

Keynote Address
Joost J. Oppenheim / Frederick, MD

Cytokines and Hematopoiesis
Manfred R. Keller / Ann Arbor, MI
Stewart D. Lyman / Seattle, WA
William P. Sheridan / Thousand Oaks, CA
Michael J.P. Lawman / Orlando, FL
Jonathan Drachman / Seattle, WA
Pamela Hunt / Thousand Oaks, CA
Connie J. Eaves / Vancouver, B.C., Canada
Katherine J. Turner / Cambridge, MA

Cytokines and Lymphopoiesis
Michael I. Lotze / Pittsburgh, PA
Serge LeBecque / Dardilly, France
David H. Lynch / Seattle, WA
Mary K. Kennedy / Seattle, WA
Teresa M. Foy / Lebanon, NH
John A. Schmidt / Rahway, NJ

Cytokines and Infectious Disease/
Cytokine Effects-Implications for Disease
Steven A. Miles / Los Angeles, CA
Steven G. Reed / Seattle, WA
William E. Paul / Bethesda, MD
Lawrence M. Lichtenstein / Baltimore, MD

Cytokine Receptors - Biological and
Clinical Implications
Marc Feldmann / London, England
Thomas A. Waldmann / Bethesda, MD
Roy A. Black / Seattle, WA

Cytokine Signal Transduction
Tadamitsu Kishimoto / Osaka, Japan
Thomas J. Schall / Palo Alto, CA
Klaus Pfizenmaier / Stuttgart, Germany
Melanie K. Spriggs / Seattle, WA
David J. Pickup / Durham, NC

Additional Speakers to be Announced

Applicants are encouraged to submit abstracts for poster presentation.

Application deadline: August 4, 1995

Information and Application Forms
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)
Cancer Susceptibility Genes and Molecular Carcinogenesis

February 19-25, 1996
The Keystone Resort, Keystone, Colorado

CONFERENCE CHAIRPERSONS
Allan Balmain / Glasgow, Scotland
Curtis C. Harris / Bethesda, MD
Kenneth Olden / Research Triangle Park, NC

SCIENTIFIC PROGRAM

Keynote Address
Harold Varmus / Bethesda, MD

Genetic Susceptibility of Animal Models - Inbred Strains
William F. Dove / Madison, WI
Norman R. Drinkwater / Madison, WI
Cheryl Lyn Walker / Smithville, TX
Peter Demant / Amsterdam, The Netherlands

Genetic Susceptibility of Animal Models - Transgenic and Knockout
Douglas Hanahan / San Francisco, CA
Tyler E. Jacks / Cambridge, MA
Michael P. Rosenberg / Research Triangle Park, NC

Genetic Susceptibility of Humans - Xenobiotic Metabolism
Frank J. Gonzalez / Bethesda, MD
Fred F. Kaelber / Jefferson, AR
Peter G. Shields / Bethesda, MD
C. Roland Wolf / Dundee, Scotland

Genetic Susceptibility of Humans - DNA Repair
Isabel Mellon / Lexington, KY
Jan H. Hoelijmakers / Rotterdam, The Netherlands

Genetic Susceptibility of Humans - Tumor Suppressor Genes
David P. Lane / Dundee, Scotland
Louise C. Strong / Houston, TX
Curtis C. Harris / Bethesda, MD

Senescence and Terminal Differentiation
J. Carl Barrett / Research Triangle Park, NC
Carol W. Greider / Cold Springs Harbor, NY
Jennifer A. Pietenpol / Nashville, TN
Harold L. Moses / Nashville, TN

Apoptosis
Tona M. Gilmer / Research Triangle Park, NC
Judith Campos / Berkeley, CA
Michael B. Kastan / Baltimore, MD
Eileen White / Piscataway, NJ
Scott W. Lowe / Cambridge, MA

Molecular Carcinogenesis in Animal Models and Humans - Skin
Allan Balmain / Glasgow, Scotland
Douglas E. Brash / New Haven, CT

Molecular Carcinogenesis in Animal Models and Humans - Liver and Breast
Henry C. Pitot / Madison, WI
Xin W. Wang / Bethesda, MD
Roger W. Wiseman / Research Triangle Park, NC
Mary-Claire King / Seattle, WA

Molecular Carcinogenesis in Animal Models and Humans - Brain
Terry A. Van Dyke / Chapel Hill, NC
Paul Kleihues / Lyon, France

Additional Speakers to be Announced

Applicants are encouraged to submit abstracts for poster presentation.
Application deadline: November 3, 1995

Information and Application Forms
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)
AACR SPECIAL CONFERENCE IN CANCER RESEARCH

Cancer: The Interface Between Basic and Applied Research

November 5-8, 1995
Stouffer Harborplace Hotel
Baltimore, MD

CONFERENCE CHAIRPERSONS
Bert Vogelstein / Baltimore, MD
Stephen H. Friend / Seattle, WA
John D. Minna / Dallas, TX

SCIENTIFIC PROGRAM

CELL CYCLE INTERVENTION
David Beach / Cold Spring Harbor, NY
Leland H. Hartwell / Seattle, WA
Joan Massague / New York, NY
Bert Vogelstein / Baltimore, MD

GENETIC INSTABILITY
Kenneth W. Kinzler / Baltimore, MD
Richard Kolodner / Boston, MA
Jeffrey M. Trent / Bethesda, MD

APOTOPSIS IN MALIGNANCY
David E. Housman / Cambridge, MA
Tyler Jacks / Cambridge, MA
Stanley J. Korsmeyer / St. Louis, MO

NEW INSIGHTS ABOUT CANCER GENES
Eric R. Fearon / New Haven, CT
Curtis C. Harris / Bethesda, MD
Wen-Hwa Lee / San Antonio, TX
Arnold J. Levine / Princeton, NJ
David M. Livingston / Boston, MA

NOVEL CANCER GENES
Stephen B. Baylin / Baltimore, MD
Donald S. Coffey / Baltimore, MD
Andrew P. Feinberg / Baltimore, MD
John D. Minna / Dallas, TX
Michael H. Wigler / Cold Spring Harbor, NY

NOVEL DRUG APPROACHES
Judah Folkman / Boston, MA
Carol W. Greider / Cold Spring Harbor, NY
Frank McCormick / Richmond, CA
Allen I. Olliff / West Point, PA
Jerry W. Shay / Dallas, TX

APPLICATION DEADLINE: August 14, 1995

Information and Application Forms:
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)
The National Center for Toxicological Research (NCTR) and four of its scientists who have contributed to our understanding of metabolic activation and DNA adduct formation in humans and experimental animals in relation to cancer risk are featured on this issue's cover. Pictured are David W. Gaylor (far left), Frederick A. Beland (second from left), Peter P. Fu (second from right), and Fred F. Kadlubar (far right).

The NCTR, in Jefferson, Arkansas, was created in 1971 by a Presidential decree that transformed the U.S. Army Pine Bluff Arsenal in Arkansas into a research center to be administered by the U.S. Food and Drug Administration (FDA) and funded jointly by the FDA, the Environmental Protection Agency (EPA), and other federal agencies. Its mission was to conduct research on the mechanisms underlying chemical toxicity at chronic low doses, with extrapolation of the results to human risk assessment, and also to foster greater understanding of the mechanisms of carcinogenesis, mutagenesis, and teratogenesis.

The first study, conducted in the 1970s, was designed to resolve the question of whether the dose-response curve of carcinogens was linear at low doses or exhibited a threshold. By using 24,000 mice to determine a dose of 2-acetylamino- fluorone (2-AAF) resulting in a 1% tumor incidence (ED01), liver tumors showed an apparent linear response, whereas bladder tumors showed a biphasic response, suggestive of a threshold. During the 1980s, a series of mechanistic studies was aimed at and helped improve our understanding of metabolic activation pathways and the nature of DNA adducts formed by over 20 different carcinogens. Extension of this knowledge to humans provides key information on interindividual susceptibility, metabolic polymorphisms, and human exposure in relation to cancer etiology and risk.

David W. Gaylor earned the Ph.D. in Statistics from North Carolina State University and joined the NCTR in 1972. He is now Director of the Division of Biometry and Risk Assessment. He was the major contributor to the design and analysis of the ED01 study, which helped in evaluation of low-dose cancer risk. He served on the Interagency Regulatory Liaison Group Committee on Risk Assessment, the National Academy of Sciences Committee on Toxicology, and the EPA Environmental Health Committee. He was awarded the honor of Fellow by the American Statistical Association and the Society of Risk Analysis, and he has received the FDA Commendable Service Award. He is the author of more than 130 papers, reviews, and book chapters.

Frederick A. Beland, Director of the Division of Biochemical Toxicology, obtained the Ph.D. in Chemistry from Montana State University and came to the NCTR in 1976. He is studying the mechanisms of carcinogenesis, with emphasis on reactive metabolites of aromatic amines, polycyclic aromatic hydrocarbons (PAHs), and the role of DNA adducts for the prediction of tumor incidence in animal bioassays. He has served on study sections for the American Cancer Society and the NIH and as an editorial advisor for Carcinogenesis and other publications. He is a Professor of Biochemistry at the University of Arkansas for Medical Sciences. He has received the FDA Commendable Service Award and the Award of Merit and has published more than 170 papers.

Peter P. Fu, Deputy Director of the Division of Biochemical Toxicology, earned the Ph.D. in Chemistry from the University of Illinois at Chicago and came to the NCTR in 1979. He is synthesizing metabolites of PAHs and determining their metabolic activation and detoxification, as well as structural factors in their metabolism, DNA binding, and tumorigenicity. He is a Professor of Pharmacology, Toxicology, and Chemistry at the University of Arkansas for Medical Sciences, the University of Arkansas at Little Rock, Providence University in Taiwan, and Guangzhou Medical College in China. He received the FDA Commendable Service Award, the Public Health Service Special Recognition Award, and the Drug Metabolism and Disposition Best Paper Award, and he has authored over 210 papers, reviews, and book chapters.

Fred F. Kadlubar, Director of the Division of Molecular Epidemiology, received the Ph.D. in Chemistry from the University of Texas at Austin and joined the NCTR in 1976. His research is focused on the metabolism and DNA adduct formation of carcinogenic aromatic amines, with an emphasis on individual susceptibility and exposure assessment in humans. He has served widely on numerous intra- and interagency committees and on the editorial boards of a number of publications, including Cancer Epidemiology, Biomarkers & Prevention, one of the journals of the American Association for Cancer Research. He is a Professor of Pharmacology and Toxicology at the University of Arkansas for Medical Sciences. He has received the FDA Commendable Service Award and is author of more than 200 papers.

We are greatly indebted to Dr. Kadlubar for the information and photographs for this cover feature.

John H. Weisburger